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Abstract 
Background: New therapeutic approaches with biologic agents such as anti-cytokine antibodies are currently on 
trial for the treatment of asthma, rhinosinusitis or allergic diseases necessitating patient selection by biomarkers. 
Allergic rhinitis (AR), affecting about 20 % of the Canadian population, is an inflammatory disease characterised by a 
disequilibrium of T-lymphocytes and tissue eosinophilia. Aim of the present study was to describe distinct cytokine 
patterns in nasal secretion between seasonal and perennial AR (SAR/PAR), and healthy controls by comparing 
cytokines regulating T-cells or stimulating inflammatory cells, and chemokines.
Methods: Nasal secretions of 44 participants suffering from SAR, 45 participants with PAR and 48 healthy controls 
were gained using the cotton wool method, and analysed for IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, GM-CSF, 
G-CSF, IFN-γ, MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES by Bio-Plex Cytokine Assay as well as for ECP and tryptase 
by UniCAP-FEIA.
Results: Participants with SAR or PAR presented elevated levels of tryptase, ECP, MCP-1, and MIP-1β, while values of 
GM-CSF, G-CSF, IL-1β, and IL-6 did not differ from the controls. Increased levels of IL-5, eotaxin, MIP-1α, and IL-17 and 
decreased levels of IFN-γ, IL-12 and IL-10 were found in SAR only. RANTES was elevated in SAR in comparison to PAR. 
Interestingly, we found reduced levels of IL-4 in PAR and of IL-13 in SAR.
Conclusions: Elevated levels of proinflammatory cytokines were seen in both disease entities. They were, however, 
more pronounced in SAR, indicating a higher degree of inflammation. This study suggests a downregulation of TH1 
and Treg-lymphocytes and an upregulation of TH17 in SAR. Moreover, the results display a prominent role of eosino-
phils and mast cells in AR. The observed distinct cytokine profiles in nasal secretion may prove useful as a diagnostic 
tool helping to match patients to antibody therapies.
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Background
Allergic rhinitis (AR) is a common disorder of the nose. 
Patients’ symptoms include nasal obstruction, rhinor-
rhoea, sneezing and nasal itching. All of them are revers-
ible spontaneously or under treatment. AR is subdivided 
into intermittent and persistent disease. Intermittent 
disease is defined by the patient having symptoms for 
less than 4 days a week or for less than 4 weeks [1]. It is 
estimated that 400 million people worldwide are affected, 
with a prevalence of AR of about 20  % in Canada and 
23  % in Europe [2–4]. Todo-Bom et  al. [5] found that 
intermittent and persistent disease are equally frequent 
in adults. AR is often associated with asthma, sinusitis, 
otitis media or nasal polyps and has a significant impact 
on patients’ quality of life [1, 6]. In addition, the disease 
imposes a substantial economic burden for society [7].
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The underlying pathology of AR is known to be a 
type 1 immediate hypersensitivity reaction. During 
the period of sensitisation, the allergen is presented 
to CD4+ T-lymphocytes inducing differentiation to 
the T-helper cell (TH) 2 phenotype. TH2-lymphocytes 
secrete cytokines which promote the differentiation 
of B cells as well as induce immunoglobulin (Ig) syn-
thesis and regulate Ig isotype switching. This results 
in increased levels of specific IgE, both local and sys-
temic [8]. In the early-phase of allergic reaction, mast 
cells, coated with specific IgE, recognise the allergen 
and release several mediators such as histamine and 
tryptase. In contrast, the late-phase is characterised by 
the secretion of chemokines like eosinophil chemotac-
tic protein (eotaxin), “regulated on activation, normal 
T cell expressed and secreted” (RANTES), and mac-
rophage inflammatory protein-1α (MIP-1α) [9], which 
induce the recruitment of eosinophils and other inflam-
matory cells. Activated eosinophils release granules 
containing amongst others eosinophil cationic protein 
(ECP) and major basic protein (MBP) [10]. In addi-
tion, eosinophils synthesise and secrete cytokines, e.g. 
interleukin (IL)-5 or granulocyte–macrophage colony-
stimulating factor (GM-CSF). Whereas the early-phase 
response to allergen exposure leads to acute symptoms, 
the late-phase reaction is held responsible for persisting 
inflammation.
AR is determined by a disequilibrium of T-helper cells 
with a predominance of TH2-type cytokines but normal 
levels of TH1-type cytokines. Another subtype of T-cells, 
regulatory T-cells (Treg), suppresses both TH1 and TH2-
type cytokine expression [11]. Thus, it has been suggested 
that in AR, an imbalance between TH2 and Treg-cells 
exists as well [10]. Concerning TH17-lymphocytes, some 
authors found elevated levels of IL-17. However, the find-
ings on IL-17 are ambiguous and the role of TH17-cells in 
AR remains unclear [12, 13].
Aim of the present study was to investigate whether 
in AR caused by a seasonal (SAR) or a perennial (PAR) 
allergen, representative cytokines and mediators in 
nasal discharge show distinct patterns picturing the 
pathophysiology. Therefore, we analysed the levels of 
cytokines and other inflammatory mediators in the nasal 
fluid of participants suffering from SAR or PAR, focus-
ing on three main topics: cytokines (1) regulating TH1 
(interferon-γ (IFN-γ), IL-12), TH2 (IL-4, IL-13), Treg (IL-
10), and TH17 (IL-17) cells, or (2) stimulating and acti-
vating inflammatory cells like granulocytes and mast 
cells (granulocyte colony-stimulating factor (G-CSF), 
GM-CSF, IL-1β, IL-5, and IL-6), and (3) chemokines 
such as eotaxin, RANTES, monocyte chemotactic pro-
tein-1 (MCP-1), or MIP-1α/β.
Methods
Study population
Clinical history was taken by one of the investigators. 
Patients presenting a history of chronic rhinosinusitis, 
nasal polyposis or aspirin sensitivity were excluded from 
the study (Table 1). Any medication concerning the nasal 
disease during 6 weeks prior to the examination consti-
tuted an exclusion criterion, especially anti-inflamma-
tory medication such as nasal steroids or antihistamines. 
Also, nasal endoscopy was performed in all participants 
in order to assess clinical signs of rhinitis and to exclude 
patients with signs of purulent rhinitis or polyposis. After 
exclusion, 137 volunteers (73 males, 64 females, mean 
age 38 ± 16 years) participated in this study.
AR was determined by the participant’s history and 
by a positive skin prick test (SPT) (ALK-Abelló, Wedel, 
Germany) for the following allergens: timothy grass, rye, 
birch, hazel, alder, beech, mugwort, ribwort, nettle, dan-
delion, house dust mite, storage mite, dog, cat and horse 
epithelial dander, alternaria, aspergillus, cladosporium, 
and penicillium; histamine dihydrochloride solution at 
1 mg/ml as positive control and allergen-free saline solu-
tion as negative control were used. The SPT was consti-
tuted positive if the diameter of the wheal was >3  mm. 
Thereafter, specific IgE to allergens tested positive in 
skin prick test was measured in serum (UniCAP-FEIA, 
Phadia, Freiburg, Germany).
SAR (n  =  44) was determined by sensitisation to at 
least one seasonal allergen with a positive skin prick 
test and a compatible positive specific IgE measure-
ment (≥0.8 kU/l) as well as typical seasonal complaints 
in participant’s history. If patient’s history did not allow a 
definite rating of the seen sensitisation with respect to its 
clinical relevance, a intranasal challenge to the suspected 
allergen was performed. Participants additionally sensi-
tised to a perennial allergen were excluded.
PAR (n  =  45) was determined by participant’s his-
tory, a sensitisation to house dust mite, animal dander, 
or perennial mold like aspergillus with a positive skin 
prick test and a specific IgE  ≥  0.8 kU/l. Moreover, an 
intranasal allergen challenge was performed in case of a 
sensitisation to house dust mite or perennial mold, or a 
Table 1 Exclusion criteria




Specific medication during the last 6 weeks
SAR Sensitisation to perineal allergen
PAR Sensitisation to seasonal allergen
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sensitisation to animal dander whose clinical relevance 
could not be clearly rated by patient’s history. Partici-
pants additionally sensitised to a seasonal allergen were 
excluded.
Healthy controls (n  =  48) presented no history of 
inflammatory nasal complaints and a negative in  vitro 
allergy screening test Sx1 (Phadia, Freiburg, Germany).
Samples were collected during as well as outside pol-
len season. Collection was not done in relation to actual 
allergen exposure or actual complaints.
The study was approved by the ethics committee of 
the medical faculty of Ludwig-Maximilians-University 
and written informed consent was obtained from all 
participants.
Biochemical and immunological methods
For sampling of nasal fluids, the cotton wool method was 
performed with minor modifications as invented by Rasp 
and coworkers [14]. Nasal secretions were gained as pre-
viously described using small cone-shaped cotton wool 
pieces (absorbent cotton, Hartmann, Heidenheim/Brenz, 
Germany) with a length of about 3  cm and a diameter 
of about 6 mm [15]. Introduced into the middle meatus 
of the nose, the cotton wool pieces were left in place for 
20 min and were subsequently centrifuged (+4 °C, 2000g) 
on a sieve for 10 min [16].
Because of partially small volumes, all samples were 
diluted 1:5 and were analysed for IL-1β, IL-4, IL-5, IL-6, 
IL-10, IL-12, IL-13, IL-17, GM-CSF, G-CSF, IFN-γ, 
MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES using 
a human cytokine 17-plex panel (Bio-Plex Cytokine 
Assay, Bio-Rad Laboratories, Hercules, California). The 
cytokine assay uses fluorescently-addressed polystyrene 
beads with conjugated capture antibodies directed to the 
above-mentioned cytokines. After washing, a fluores-
cently marked detection antibody builds an immunoas-
say with the cytokine. For analysis, two lasers excite the 
fluorochromes: one for classifying each bead, the other 
for quantifying the amount of analyte bound [17]. Detec-
tion levels were 0.5 pg/ml.
ECP and tryptase were measured by ELISA (UniCAP-
FEIA, Phadia, Freiburg, Germany). Thresholds for detec-
tion were 10 ng/ml for ECP and 5 ng/ml for tryptase.
Statistics
SigmaPlot for Windows version 11.0 software (Systat 
Software, San José, California, USA) was used for sta-
tistical evaluation and graphical presentation. All data 
failed normality testing (Shapiro–Wilk). Therefore, the 
Kruskal–Wallis One Way Analysis of Variance (ANOVA) 
on Ranks was used for testing a statistically significant 
difference in the median values among the three groups. 
To isolate the group or groups that differ from the 
others, the All Pairwise Multiple Comparison Procedures 
(Dunn’s Method) was used in the following step. p values 
<0.05 were regarded as significant. For graphic presenta-
tion of results, data is given in a box plot with the median 
(horizontal line within the box), the 25th and 75th per-
centile (boundary of the box), and the 10th and 90th per-
centile (whiskers above and below the box). Significances 
are graphically represented between the corresponding 
plots: * indicates p value <0.05, ** p value <0.01, and *** p 
value <0.001.
Results
44 participants suffering from SAR, 45 participants suf-
fering from PAR and 48 healthy subjects were included 
in this study. Demographics and sensitisation profiles 
are depicted in Table  2. The mean age varied from 36 
to 40  years. The highest percentage of subjects suffer-
ing from asthma was found in the SAR group, followed 
by the PAR group and the controls. Participants suffering 
from SAR were frequently sensitised to grass and birch 
while house dust mite and animal dander were the main 
antigens in PAR. In SAR as well as in PAR one participant 
(2 %) was sensitised to mold with alternaria (seasonal) or 
aspergillus (perennial) being the relevant allergen.
AR is a TH2 dominated disease. Therefore, an increase 
of TH2 cytokines and possibly a decrease of TH1 and Treg 
cytokines could be expected. Concerning the markers 
of TH2 induced B cell stimulation, we did not find ele-
vated levels of either IL-4 nor IL-13. As shown in Fig. 1a, 
similar levels of IL-4 were found in SAR (median 7  pg/
ml, range 2–17  pg/ml) and controls (median 7  pg/ml, 
range 0–32 pg/ml), but significantly lower levels in PAR 
(median 4  pg/ml, range 0–38  pg/ml) compared to con-
trols as well as to SAR (p < 0.001 vs. controls/SAR). The 
quantity of IL-13 was decreased in SAR (median 11 pg/
ml, range 6–137  pg/ml) compared to both the controls 
(median 19  pg/ml, range 10–32  pg/ml; p  <  0.001) and 
Table 2 Demographic data and results of specific IgE
n.d. not determined
Controls SAR PAR
Participants (N) 48 44 45
Mean age (years) 40 37 36
Gender ♀/♂ (%) 62/38 34/66 42/58
Asthma (%) 9 24 18
Poaceae (%) n.d. 83 0
Betulaceae (%) n.d. 52 0
Asteraceae (%) n.d. 12 0
House dust mite (%) n.d. 0 82
Mold (%) n.d. 2 2
Animal dander (%) n.d. 0 27
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PAR (median 19  pg/ml, range 7–48  pg/ml; p  <  0.001) 
(Fig. 1b).
As pictured in Fig. 2a, b, a decrease of the TH1 marker 
cytokines IFN-γ and IL-12 was found in SAR (IFN-γ: 
median 85 pg/ml, range 5–299 pg/ml; p < 0.01 vs. control, 
p  <  0.001 vs. PAR; and IL-12: median 111  pg/ml, range 
45–299  pg/ml; p  <  0.001 vs. control/PAR) compared to 
PAR (IFN-γ: median 118  pg/ml, range 18–822  pg/ml; 
and IL-12: median 180 pg/ml, range 71–348 pg/ml) and 
the controls (IFN-γ: 107 pg/ml, range 34–551 pg/ml; and 
IL-12: median 200 pg/ml, range 59–358 pg/ml).
Moreover, the quantity of the mainly Treg cell released 
cytokine IL-10 was lower in SAR (median 47  pg/ml, 
range 21–139 pg/ml) than in the controls (median 73 pg/
ml, range 31–158  pg/ml; p  <  0.001) and PAR (median 
61 pg/ml, range 21–118 pg/ml; p < 0.01) (Fig. 3).
IL-17 levels, representing TH17 activity, were sig-
nificantly elevated in the SAR group (median 20  pg/
ml, range 0–90 pg/ml; p < 0.001 vs. control/PAR) while 
the PAR group and the controls showed similar low lev-
els (PAR: median 0 pg/ml, range 0–147 pg/ml; controls: 
median 2 pg/ml, range 0–320 pg/ml) (Fig. 4).
Investigating the stimulation and activation of inflam-
matory cells, several degranulation products and 
cytokines were measured. Depicted in Fig.  5a, a com-
































Fig. 1 Levels of IL-4 and IL-13 in nasal fluid in controls, SAR and PAR: box plots of the levels of IL-4 (a dark grey) and IL-13 (b light grey) in nasal 
secretion are shown. IL-4 is significantly decreased in PAR compared to the controls as well as the SAR group. IL-13 is significantly decreased in SAR 



































Fig. 2 Levels of IFN-γ and IL-12 in nasal fluid in controls, SAR and PAR: box plots of the levels of IFN-γ (a dark grey) and IL-12 (b light grey) in nasal 
secretion are shown. IFN-γ is significantly decreased in SAR compared to the controls or PAR. IL-12 is significantly decreased in SAR compared to the 
controls as well as to PAR. **p < 0.01; ***p < 0.001
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activation in nasal mucosa revealed an increase in SAR 
(median 116 ng/ml, range 0–1000 ng/ml; p < 0.001) and 
PAR (median 43  ng/ml, range 0–1000  ng/ml; p  <  0.01) 
compared to the controls (median 20  ng/ml, range 
0–467  ng/ml). Likewise, tryptase levels displaying mast 
cell activation were significantly elevated in the nasal 
secretions of the SAR (median 20 ng/ml, range 0–452 ng/
ml; p  <  0.001) and the PAR group (median 9  ng/ml, 
range 0–1000  ng/ml, p  <  0.001) compared to con-
trols (median 0  ng/ml, range 0–94  ng/ml) (Fig.  5b). As 
shown in Table 3, for G-CSF and GM-CSF, no significant 
differences among the three groups were found. Also, the 
amount of IL-1β in the nasal secretions was rather simi-
lar in all groups. Levels of IL-5 in SAR were significantly 
increased over the controls. However, no statistically 
significant difference between the controls and PAR was 
seen. The measurement of IL-6 revealed no differences 
among the three groups.
Also displayed in Table 3 are the levels of chemokines 
in nasal discharge of AR participants and controls. An 
elevation of eotaxin was found in SAR compared to PAR. 
Concerning RANTES, higher levels were detected in 
SAR than in PAR whereas no significant difference could 
be seen between the control group and either of the AR 
groups. In comparison to the controls, elevated levels of 
MCP-1 were found in both AR groups. MIP-1α showed 
a significantly elevated level in the SAR group compared 
to control as to PAR. For MIP-1β, compared to control 
(median 103  pg/ml, range 0–2049  pg/ml), an increase 
was found in SAR (median 226 pg/ml, range 16–1769 pg/
ml; p < 0.001) as well as in PAR (median 161 pg/ml, range 
0–2138 pg/ml; p < 0.05) (Fig. 6).
Discussion
Nasal secretion is easily accessible and Bio-Plex Cytokine 
Assay is simple to perform. Thus, it constitutes a method-
ological approach possibly applicable in clinical routine. 
Cytokines in the nasal fluid of participants suffering from 
SAR or PAR were analysed in a true-to-life clinical set-
ting. Aim of the present study was to investigate whether 
in AR, representative cytokines in nasal discharge show 
distinct patterns proving the used methodology helpful 
for endotyping of inflammatory nasal diseases.
For a lifelike approach, we chose to collect the samples 
neither during specific seasons of the year nor after aller-
gen provocation. In SAR, the participants’ exposition to 
aeroallergens depends not only on the absolute amount 
of antigens in the air but also on the habitation, profes-
sion and habits of the individual participant as well as 
his efforts of abstention. Likewise, it is difficult to find 
objective measurements for the individual pollination in 
PAR participants’ everyday life which also varies in the 
course of the year [18]. We thus refrained from deter-
mining the exact pollution with antigens. Moreover, not 
using subjective or objective measures of AR, we did not 
know if participants were actually suffering from AR at 
the time of sample collection. The magnitude of the aller-
gic response is associated with the preseasonal values of 
IgE [8] and the levels of cytokines were found to differ 
between atopic and non-atopic subjects during as well as 
outside the pollen season [19]. Addressing the important 
question of trends in cytokine levels over time, longitudi-




















Fig. 3 Levels IL-10 in nasal fluid in controls, SAR and PAR: box plot of 
IL-10 levels in nasal secretion is shown. IL-10 is significantly decreased 
















Fig. 4 Levels IL-17 in nasal fluid in controls, SAR and PAR: box plot of 
IL-17 levels in nasal secretion is shown. IL-17 is significantly increased 
in SAR compared to both the controls and PAR. ***p < 0.001
Page 6 of 10König et al. Allergy Asthma Clin Immunol  (2015) 11:26 
IL-4 and IL-13 are produced by TH2-cells and other 
inflammatory cells such as mast cells, eosinophils 
or basophils [20]. In the pathology of allergy, similar 
responses to these cytokines are known. They act in 
concert or alone to induce differentiation of TH-cells, 
migration of T-cells and eosinophils, Ig class switch-
ing or mucus secretion [20, 21]. In the present study, we 
surprisingly found normal or decreased levels of these 
TH2 characterising cytokines, contradicting an expected 
upregulation, which would lead to stimulation of IgE 
production. Previous studies on IL-4 and IL-13 revealed 
normal or elevated levels in nasal secretions under nat-
ural allergen exposure, while increases were reported 
after provocation tests [9, 15, 19, 22]. One group found 
decreased levels of IL-4 in SAR patients [23]. We 
measured the cytokine levels without prior nasal allergen 
challenge, which might explain the missing elevations in 
our study. On the one hand it might be concluded that 
the amount of allergens in natural environment is not 
high enough to provoke profuse production of IL-4 and 
IL-13 but on the other hand this cannot explain decrease. 
No definite explanation can be given to the normal or 
even decreased values of IL-4 and IL-13, a methodologi-
cal cause cannot be ruled out.
Although allergy is known to be a TH2-dominated dis-
ease, the role of other T-cell subsets was also of interest 
in the presented work. IL-12 and IFN-γ are well-known 
indicators of TH1-type inflammation and crucial to 
induction and maintenance of TH1 response, activating 




































Fig. 5 Levels of ECP and tryptase in nasal fluid in controls, SAR and PAR: box plots of the levels of ECP (a dark grey) and tryptase (b light grey) in nasal 
secretion are shown. ECP is significantly elevated in SAR and PAR compared to controls. Tryptase is significantly elevated in SAR and PAR compared 
to controls. **p < 0.01; ***p < 0.001
Table 3 Cytokine levels in nasal fluid in healthy controls, SAR and PAR patients
Concentrations are given in pg/ml. Data are presented as median (upper line) and range (lower line)
n.s. not significant
IL-1β IL-5 IL-6 G-CSF GM-CSF Eotaxin RANTES MCP-1 MIP-1α
Controls 20 5 25 90 32 45 9 66 0
4–1000 1–238 0–3036 9–7962 0–137 0–154 0–259 17–401 0–113
SAR 33 13 39 165 28 67 16 94 8
2–1677 0–829 5–443 10–10,681 0–115 0–503 0–766 30–600 0–66
PAR 31 6 32 146 27 30 0 93 0
5–7894 1–761 0–397 0–17,211 0–149 0–220 0–509 0–866 0–119
p values
 SAR-Con n.s. <0.05 n.s. n.s. n.s. n.s. n.s. <0.01 <0.001
 PAR-Con n.s. n.s. n.s. n.s. n.s. n.s. n.s. <0.05 n.s.
 SAR-PAR n.s. n.s. n.s. n.s. n.s. <0.001 <0.01 n.s. <0.001
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25]. Moreover, these cytokines counteract the differen-
tiation of TH2 and TH17 [24]. In our study, the levels of 
IL-12 and IFN-γ were both decreased in SAR but not in 
PAR. This points to a downregulation of TH1-lympho-
cytes in SAR.
Having the ability to reduce Ig production and tis-
sue eosinophilia as well as TH2- and TH17-dependent 
reactions, regulatory T-cells are essential in maintain-
ing peripheral tolerance. Allergen-specific Treg-cells 
have been reported to be diminished in PAR and have 
decreased suppressive capacity in SAR [26]. IL-10 is 
an immunomodulatory cytokine which, together with 
tumor growth factor (TGF)-β, is important for Treg oper-
ability. Previous studies on the levels of IL-10 revealed 
discordant data. Unchanged or increased levels were 
found in naïve nasal secretions of SAR patients, while 
IL-10 was elevated after allergen provocation and specific 
immunotherapy [12, 22, 26]. Our results might suggest a 
diminished influence of Treg-cells in SAR, illustrating the 
impaired peripheral tolerance in AR. However, no final 
conclusion on Treg can be drawn based on our results 
as IL-10 is produced by other cell types like TH2 cells as 
well.
IL-17 is a cytokine with proinflammatory proper-
ties influencing diverse cells. IL-17 producing cells, 
named TH17, were discovered in the beginning of this 
century. Though TH17-lymphocytes were a subject 
of interest in recent years, their role in AR remains 
unclear. Scadding suspects elevated levels of this 
cytokine, predominantly in PAR [12]. Our study does 
not support this thesis, showing an elevation of IL-17 
in SAR but undetectable levels in the majority of the 
PAR samples. This is in line with a previous study 
reporting no elevation of IL-17 in nasal discharge of 
PAR patients [15].
Concerning the role of the discussed T-cell subsets 
in AR, our results suggest a downregulation of TH1 and 
Treg-lymphocytes especially in SAR. This indicates an 
imbalance between the different T-cell subsets result-
ing in an impaired tolerance to allergens. Furthermore, 
increased markers of TH17 activity were found in AR 
leaving this T-cell subset as a field of future research.
Mast cells, activated by antigen and IgE, immediately 
release preformed mediators such as histamine, seroto-
nin, and tryptase. Moreover, stimulated mast cells newly 
produce a number of other mediators, which are released 
during the late-phase of allergic reaction [27]. We utilised 
tryptase as a marker of mast cell activation and detected 
elevated levels in both SAR and PAR. This is concord-
ant with previous reports of elevated levels of tryptase 
caused by natural or artificial allergen exposure [28, 29] 
and emphasises the importance of mast cells in AR.
As the eosinophil is one of the predominant cell types 
in AR, we measured two indicators of eosinophil activa-
tion, ECP and IL-5. The level of ECP, which is secreted 
by eosinophils and important in the defence of patho-
gens, correlates positively with the number of nasal 
eosinophils [14, 30]. Consistent with previous reports, 
our study found significantly elevated levels of ECP [14]. 
The amount of nasal ECP was sixfold higher in SAR and 
doubled in PAR in comparison to the controls. IL-5, pri-
marily produced by mast cells and TH2-lymphocytes, is 
thought to be responsible for eosinophil survival, chemo-
taxis, and activation [31]. This makes this cytokine a sec-
ond suitable indicator of eosinophil activation. Just as for 
ECP, we found elevated levels in SAR, highlighting the 
importance of eosinophils in this disease entity. However, 
the concentration of IL-5 in PAR was in normal range. 
We conclude that the role of eosinophils might be less in 
PAR than in SAR, and other factors are more important 
in maintaining the more chronic inflammation. The ele-
vated level of IL-5 in SAR might also be a possible thera-
peutic target. Pavord et al. [32] found reduced numbers 
of eosinophils in blood samples of asthmatics treated 
with an monoclonal antibody against IL-5. In conclusion, 
we found elevated levels of markers of eosinophil activa-
tion in both AR groups. However, the effect was more 
pronounced in SAR, suggesting a greater influence of 
eosinophils in SAR than in PAR.
Concerning the next group of cytokines, the colony-
stimulating factors, surprisingly no increases could be 
shown. GM-CSF is a multifunctional proinflammatory 
cytokine produced by a host of different cells, amongst 
them epithelial cells, mononuclear cells or eosino-
phils. It acts locally in the nose stimulating dendritic 



















Fig. 6 Levels of MIP-1β in nasal fluid in controls, SAR and PAR: box 
plot of MIP-1β levels in nasal secretion. MIP-1β is significantly elevated 
in SAR as well as in PAR compared to controls. *p < 0.05; ***p < 0.001
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GM-CSF induces proliferation and differentiation of stem 
cells [33]. An increase of GM-CSF in AR patients was 
reported [9]. However, we could not reproduce this find-
ing, which might be due to the fact that our samples were 
taken without prior allergen provocation. For G-CSF, we 
did not find a statistically significant increase in either of 
the groups as well. G-CSF is known to regulate prolifera-
tion of haematopoietic progenitor cells and to influence 
neutrophil function. As most groups did not examine the 
amount of G-CSF in AR, little is known about its impact 
on AR. Pelikan [34] found elevated levels in tears of SAR 
patients after allergen provocation, providing evidence 
for an influence of G-CSF in this disease entity. But fur-
ther research is needed to define its role in allergy.
We also measured the amount of two well-established 
proinflammatory cytokines, IL-1β and IL-6. For both 
cytokines, no statistically significant difference between 
the three groups was found. IL-1β and IL-6 are rather 
unspecific markers of inflammation. Various inflamma-
tory cells are able to produce these pleiotropic cytokines. 
Physiologically, IL-1β and IL-6 influence the growth and 
maturation of immune cells as well as haematopoiesis. 
Furthermore, they are involved in auto-inflammatory dis-
eases and oncogenesis [35, 36]. Data on these two general 
markers of inflammation in nasal fluids are inconsist-
ent [12]. Pelikan [34] did not find elevated levels of IL-6 
in tears of allergic subjects. This is consistent with our 
results, but disagrees with an elevation of IL-1β and IL-6 
found by others [9]. An explanation could be that we 
examined nasal secretions under natural allergen expo-
sure while elevated levels were described after experi-
mental allergen challenge.
The late-response of allergic reaction is characterised 
by the influx of inflammatory cells into the site of inflam-
mation. In this process, chemokines play a crucial role. 
To measure the recruitment of eosinophils, we examined 
three chemokines potently attracting these cells: eotaxin, 
RANTES, and MIP-1α. For all three, the concentration 
in nasal secretions of SAR participants was increased. 
Eotaxin, a specific eosinophil attractant, was elevated 
in SAR over the PAR group. Our results affirm the find-
ings of Chawes et  al. [22], who found elevated levels of 
eotaxin in nasal secretions of SAR patients under natural 
allergen exposure. Moreover, an increase of eotaxin posi-
tive cells and eosinophils in nasal biopsies was reported 
after allergen provocation [37]. Concerning RANTES, 
there was a significant elevation in SAR over PAR, while 
the differences between either of the AR groups and 
the controls were not significant. RANTES is not only 
known to attract eosinophils but also to cause activa-
tion of eosinophils and basophils resulting in inflamma-
tory mediator release [21]. Further, elevated levels were 
reported after nasal allergen challenge [9]. The levels of 
MIP-1α were significantly increased in SAR participants. 
MIP-1α is produced by a number of inflammatory cells 
and is able to attract granulocytes as well as to activate 
eosinophils, to stimulate T-cells and to regulate Ig pro-
duction [21, 38]. It is reported to be elevated after nasal 
allergen challenge [9, 12]. Interestingly, this chemokine 
was not detectable in the majority of our controls or PAR 
participants, while in SAR, most participants had detect-
able levels of MIP-1α. In summary, our results show an 
increase of eosinophil attractants in SAR. This is in line 
with the elevated levels of ECP and IL-5, emphasising the 
prominent role of eosinophils in SAR, while the normal 
levels of IL-5 and just slightly elevated levels of ECP in 
PAR indicate a minor role of eosinophils in the chronic 
inflammation of PAR.
The levels of MCP-1 and MIP-1β were elevated in 
either of the AR groups. Increased MCP-1 and MIP-1β 
release has been reported under natural exposure as well 
as after allergen provocation in SAR subjects [12, 22]. 
MCP-1 potently attracts and activates monocytes and 
basophils, and recruits macrophages and neutrophils 
[38, 39]. Secreted by monocytes, natural killer cells and 
activated lymphocytes, MIP-1β recruits lymphocytes, 
natural killer cells and immature dendritic cells [40]. The 
elevation of these two chemokines clearly shows that in 
both SAR and PAR, a bunch of diverse inflammatory cells 
is recruited. Our results thus support the concept of min-
imal persistent inflammation in PAR [41]. This concept 
states a persistent infiltration of neutrophils under con-
tinuous low allergen exposure while eosinophils and mast 
cells have minor influence.
Conclusions
Aim of our study was to find distinct cytokine profiles in 
nasal discharge of AR participants in a lifelike approach, 
which might be useful for diagnostic purposes. Evaluat-
ing our results, ECP, tryptase, MCP-1, and MIP-1β are 
suitable markers to differentiate AR participants from 
healthy subjects. Furthermore, in SAR eotaxin, MIP-1α, 
and IL-17 are elevated in comparison to both PAR par-
ticipants as well as controls. In addition, reduced levels of 
IFN-γ and IL-10 are found. Moreover, SAR and PAR can 
be distinguished by the levels of RANTES. Even though 
some questions remain unanswered, we have demon-
strated that the methodology used in this study could 
be developed into a diagnostic tool for “endotyping” of 
patients in daily clinical routine. If such an “endotyping” 
is feasible in nasal discharge, this method is superior to 
immunohistochemical analysis of nasal biopsy specimen 
because nasal discharge is easily accessible and collec-
tion is harmless to the patient. Further research is needed 
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to describe the cytokine patterns in nasal fluid of pure 
CRS with or without nasal polyps followed by examina-
tions of mixed forms of CRS and AR. In the long term, 
easily accessible biomarkers could help to match patients 
with innovative therapeutic approaches like anti-cytokine 
antibodies. Uncovering specific endotypes out of clini-
cally similar phenotypes might result in a more targeted, 
individualised therapy beneficial to the patient.
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